Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1
- Registration Number
- NCT04372927
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Etoposide in Patients With COVID-19 Infection
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT04356690
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
AflacLL1901 (CHOA-AML)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT04326439
- Locations
- 🇺🇸
Egleston Hospital, Atlanta, Georgia, United States
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: CarboplatinProcedure: Computed TomographyDrug: CyclophosphamideDrug: DoxorubicinDrug: EtoposideDrug: IfosfamideDrug: IrinotecanProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Radiation TherapyProcedure: Surgical ProcedureProcedure: Transabdominal UltrasoundDrug: TopotecanDrug: VincristineProcedure: X-Ray Imaging
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT04322318
- Locations
- 🇺🇸
Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT04301076
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: AsparaginaseDrug: Asparaginase Erwinia chrysanthemiProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyBehavioral: Cogstate Assessment BatteryProcedure: Computed TomographyDrug: CytarabineDrug: EtoposideDrug: Dexrazoxane HydrochlorideDrug: Daunorubicin HydrochlorideOther: Fludeoxyglucose F-18Drug: Gemtuzumab OzogamicinDrug: Gilteritinib FumarateDrug: Liposome-encapsulated Daunorubicin-CytarabineDrug: MethotrexateProcedure: Magnetic Resonance ImagingDrug: Mitoxantrone HydrochlorideProcedure: Positron Emission TomographyDrug: Therapeutic Hydrocortisone
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1400
- Registration Number
- NCT04293562
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT04256421
- Locations
- 🇺🇸
Texas Oncology Cancer Center, Austin, Texas, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Blue Ridge Cancer Care, Roanoke, Virginia, United States
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 738
- Registration Number
- NCT04234607
- Locations
- 🇨🇳
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma
- Conditions
- Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaT-Cell/Histiocyte-Rich Large B-Cell LymphomaGray-Zone Lymphoma
- Interventions
- Drug: Polatuzumab VedotinBiological: RituximabDrug: PrednisoneDrug: EtoposideDrug: DoxorubicinDrug: CyclophosphamideProcedure: Multigated Acquisition ScanBiological: GlofitamabProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyProcedure: Computed TomographyProcedure: Bone Marrow BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 56
- Registration Number
- NCT04231877
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.